In addition, approximately 1% of the patients with lung cancer who were treated with anti-PD(L)1 agents developed a myocardial infarction or stroke within the first 6 months after the initiation of therapy, suggesting that these adverse events resulted from effects on existing atherosclerotic plaques and not from the de novo development of atherosclerotic lesions [34]. The gene discussed is CD274; the disease is lung cancer.